PCSK9 antibodies: safety and efficacy of Alirocumab and Evolocumab
Inhibition of proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) has been intensively studied to lower low-density lipoprotein cholesterol ( LDL-C ) levels.
The purpose of this meta-analysis was to evaluate the safety and efficacy of anti-PCSK9 antibodies in randomized, controlled trials ( RCTs ).
Safety outcomes were rates of common adverse events. Efficacy outcomes included percentages of LDL cholesterol lowering and other lipid changes compared with placebo and Ezetimibe, respectively.
Twenty-five RCTs encompassing 12,200 patients were included.
The rates of common adverse events were firstly reported in the study by pooling together all evidence in RCTs, showing largely no significant difference between anti-PCSK9 antibodies and placebo ( or Ezetimibe ), except that Alirocumab ( Praluent ) was associated with reduced rates of death ( relative risk, RR=0.43, 95 % confidence interval (CI): 0.19 to 0.96, P = 0.04 ) and an increased rate of injection-site reactions ( RR=1.48, 95 % CI: 1.05 to 2.09, P = 0.02 ); Evolocumab ( Repatha ) reduced the rate of abnormal liver function ( RR=0.43, 95 % CI: 0.20 to 0.93, P = 0.03 ), both compared with placebo.
No significant difference in safety outcomes was detected between monthly 420 mg and biweekly 140 mg Evolocumab treatments.
Monthly 420 mg Evolocumab treatment significantly reduced LDL cholesterol by -54.6 % ( 95 % CI: -58.7 to -50.5 % ) and by absolute -78.9 mg/dl ( 95 % CI: -88.9 to -68.9 mg/dl ) versus placebo, and by -36.3 % ( 95 % CI: -38.8 to -33.9 % ) versus Ezetimibe ( Zetia ), and increased high-density lipoprotein cholesterol ( HDL-C ) by 7.6 % ( 95 % CI: 5.7 to 9.5 % ) versus placebo and 6.4 % ( 95 % CI: 4.3 to 8.4 % ) versus Ezetimibe.
An equal or even greater change was observed following biweekly 140 mg administration.
Significant and favorable changes were also detected in other lipids following Evolocumab treatment.
Biweekly 50 to 150 mg Alirocumab lowered LDL cholesterol by -52.6 % ( 95 % CI: -58.2 to -47.0 % ) versus placebo, by -29.9 % ( 95 % CI: -32.9 to -26.9 % ) versus Ezetimibe, and increased HDL cholesterol by 8.0 % ( 95 % CI: 4.2 to 11.7 % ) versus placebo.
In conclusion, Evolocumab and Alirocumab were safe and well-tolerated from the most-powered analyses.
Both antibodies substantially reduced the LDL cholesterol level by over 50 %, increased the HDL cholesterol level, and resulted in favorable changes in other lipids. ( Xagena )
Zhang XL et al, BMC Med. 2015;13:123. doi: 10.1186/s12916-015-0358-8.
The ODYSSEY OUTCOMES ( Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab ) trial compared...
European Union has approved Praluent to reduce the risk of cardiovascular events in patients with established cardiovascular disease
The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular (...
Praluent to prevent myocardial infarction, stroke and unstable angina requiring hospitalization, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...
Heterozygous familial hypercholesterolemia: individualized low-density lipoprotein cholesterol reduction with Alirocumab titration strategy
Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...
ODYSSEY Alirocumab trials: lower major adverse cardiovascular events risk with lower LDL cholesterol levels
In statin trials, men and women have shown similar relative risk reductions in cardiovascular events per 39 mg/dL low-density lipoprotein...
Long-term safety and efficacy of Alirocumab in patients with heterozygous familial hypercholesterolemia
ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...
Heterozygous familial hypercholesterolemia: 63% of patients treated with Alirocumab no longer required apheresis
Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...
A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin...
Anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia: systematic review of published phase 3 data
Two anti-proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) monoclonal antibodies, Alirocumab and Evolocumab, have been approved for the treatment...
ODYSSEY LONG TERM trial: robust and consistent LDL cholesterol lowering demonstrated with Alirocumab, a PCSK9 inhibitor
The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...